ERBB2 and cancer: In the current manuscript, we conducted a survey by the DELPHI method to collect opinions on various prognostic factors/tools used to estimate the cancer recurrence risk and thereby plan therapy in HR+, HER2/neu negative BC patients; that could be used pragmatically by oncologists of India, SAARC and LMIC countries in day-to-day clinical practice.